Yulia Yu. Andreeva

Yulia Yu. Andreeva

Auto-generated profile, based on publicly available information

Yulia Yu. Andreeva

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
NDN.V. Danilova
N.V. Danilova
ACA.V. Chayka
A.V. Chayka
VKV.M. Khomyakov
V.M. Khomyakov
NON.A. Oleynikova
N.A. Oleynikova
YAYu.Yu. Andreeva
Yu.Yu. Andreeva
PMPavel G. Malkov
Pavel G. Malkov
Evaluation of the frequency of microsatellite instability in gastric adenocarcinomas in patients of the Russian Federation, determination of the relationship of microsatellite instability with clinical and morphological characteristics and the impact on the prognosis. We used samples of surgical material from 310 patients with a verified diagnosis of gastric cancer. The age of the patients ranged from 22 to 85 years (mean 63 years). The median follow-up of patients was 83 months. Each sample was immunohistochemically stained with antibodies to microsatellite instability markers MLH1, MSH2, MSH6, and PMS2. The results were compared with the main clinical and morphological characteristics of gastric cancer and data on patient survival. The frequency of detection of MMR-negative tumors in the Russian population is 8.1% of all patients with gastric cancer. It was found that patients with MMR-negative gastric carcinomas are older (mean age 69 years, p=0.008). In this group predominates distal localization of tumors, type 2 according to R. Bormann classification (p=0.010), tubular histological type (p=0.010), intestinal subtype according to P. Lauren classification (p=0.003). There were no significant differences between MMR-negative and MMR-positive tumors in terms of other clinical and morphological parameters (including the stage of the tumor process). The overall median survival of patients with MMR-negative tumors was 76%, which significantly (p=0.013) exceeds that in the group of MMR-positive tumors (36%). It was found that despite significant differences in survival, MMR-status is not an significant prognostic factor in gastric cancer (HR=0.983). The established differences in patient survival make it possible to distinguish a group of MMR-negative tumors into a separate pathogenetic subtype of gastric cancer (MSI subtype) based on immunohistochemical studies. This subtype occurs predominantly in elderly patients with tubular gastric adenocarcinomas and is characterized by a favorable prognosis.

21 March 2022 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
GDGrigory Demyashkin
Grigory Demyashkin
TBTatyana G. Borovaya
Tatyana G. Borovaya
YAYulia Yu. Andreeva
Yulia Yu. Andreeva
ANAndrey Nedorubov
Andrey Nedorubov
YSYulia Stepanova
Yulia Stepanova
AKAndrei Kaprin
Andrei Kaprin
Leukocyte-poor platelet-rich plasma (LP-PRP) has a potential influence on tissue regeneration by stimulating proliferation and differentiation of progenitor cells.The aim of this work is morphologi...

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
LZL.E. Zavalishina
L.E. Zavalishina
EOE.M. Oliushina
E.M. Oliushina
YAYu.YU. Andreeva
Yu.YU. Andreeva
OKO.A. Kuznetsova
O.A. Kuznetsova
LML.V. Moskvina
L.V. Moskvina
GFG.A. Frank
G.A. Frank
Updated 2023 guidelines from the College of American Pathologists (CAP) on immunohistochemical detection of human epidermal growth factor receptor type 2 (HER2), receptors of estrogen (ER) and progesterone (PgR), and the cell proliferation marker Ki-67 in breast cancer are presented. Attention is drawn to the emergence of two new terms «ER Low Positive» and «HER2 Low» to characterize tumors with low expression of estrogen receptors and HER2.

1 January 2022 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
GDGrigory Demyashkin
Grigory Demyashkin
TBT.G. Borovaya
T.G. Borovaya
YAYu.Yu. Andreeva
Yu.Yu. Andreeva
SKS.N. Koryakin
S.N. Koryakin
MVMatvey Vadyukhin
Matvey Vadyukhin
VSV.I. Shekin
V.I. Shekin
The number of cases of male infertility is steadily growing every year, and therefore it is necessary to develop new methods for the diagnosis and treatment of this disease. It is known that plasma enriched with platelets, the α-granules of which contain growth factors, possesses high regenerative activity; therefore, we can expect positive results from its use for the restoration of spermatogenic epithelium. Morphological assessment of spermatogenesis after local β-irradiation with a dose of 8 Gy and the introduction of growth factors. Wistar rats (n=135) were divided into groups: I - Control, II - 8IR, III - 8IR+LP-PRP+IGF, IV - 8IR+LP-PRP, and V - LP-PRP. Spermatogenesis in animals of groups II, III, and IV was inhibited by a single local irradiation with 8 Gy electrons. Then, for 11 weeks, LP-PRP was injected intraperitoneally to rats III and IV, and in group III - additionally IGF-1. The testes were examined by light microscopy, computer morphometry, micro-CT, and Western blotting. After irradiation, a decrease in spermatogenic epithelium and the number of germ cells was observed up to sub- and total germinal aplasia, fibrosis and an increase in the expression of caspase-3. Against the background of LP-PRP+IGF administration, the decrease in the proportion of germ cells (hypospermatogenesis) was less pronounced. The introduction of growth factors and other biologically active substances released from the α-granules of LP-PRP platelets leads to a delayed decrease in the quantitative and qualitative indicators of spermatogenesis, and the additional administration of IGF-1 enhances the regenerative processes that counteract the development of the effects of electron irradiation with a dose of 8 Gy.

1 January 2022 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
NDN.V. Danilova
N.V. Danilova
TST.N. Sotnikova
T.N. Sotnikova
Dmitry V KalininDmitry V Kalinin
Dmitry V Kalinin
NON.A. Oleynikova
N.A. Oleynikova
ACA.V. Chayka
A.V. Chayka
PMPavel G. Malkov
Pavel G. Malkov
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка частоты выявления экспрессии PD-L1 в EBV-ассоциированных аденокарциномах желудка, уточнение связи экспрессии PD-L1 с клинико-морфологическими характеристиками и ее влияния на прогноз заболевания у пациентов с EBV-ассоциированным раком желудка. МАТЕРИАЛ И МЕТОДЫ В исследовании использованы образцы операционного материала от 127 пациентов с раком желудка. Каждый образец был окрашен методом гибридизации in situ с использованием праймеров к малым вирусным РНК вируса Эпштейна—Барр (EBER), а также антителами к PD-L1 (клоны SP263, SP142). Полученные результаты были сопоставлены с основными клинико-морфологическими характеристиками рака желудка и данными по выживаемости пациентов. РЕЗУЛЬТАТЫ Среди EBV-ассоциированных раков желудка частота выявления положительного PD-L1-статуса (SP263) составила 100%, а PD-L1-статуса (SP142) — 76,9%, таким образом, положительный PD-L1-статус (SP263, SP142) значимо чаще выявляется в EBV-ассоциированных карциномах желудка. Установлено, что пациенты с положительным PD-L1-статусом в EBV-ассоциированных карциномах желудка отличаются более молодым возрастом (средний возраст 56,3 года для SP263 и 55,6 года для SP142), принадлежностью к мужскому полу. Также в данной группе преобладают проксимальная локализация опухолей, язвенная форма роста, тубулярный гистологический тип, промежуточный подтип по P. Lauren. Данные характеристики не зависят от исследованного клона антител: положительный PD-L1-статус с антителами к SP142 и SP263 выявляется у одних и тех же пациентов, за небольшим исключением. Общая медиана выживаемости пациентов с наличием положительного PD-L1-статуса SP263 в EBV-ассоциированных карциномах желудка составила 35 мес, пациентов с наличием положительного PD-L1-статуса SP142 — 25 мес. Медиана выживаемости пациентов с положительным PD-L1-статусом SP142 выше по сравнению с общей медианой выживаемости пациентов с отрицательным PD-L1-статусом в EBV-ассоциированных карциномах желудка, составляющей 15 мес. Установлено, что PD-L1-статус в EBV-ассоциированном раке желудка не является значимым прогностическим признаком. ЗАКЛЮЧЕНИЕ Отдельно взятый PD-L1-статус не оказывает значимого влияния на прогноз у пациентов с раком желудка, в том числе в группе EBV-ассоциированных карцином, и может рассматриваться только в совокупности с «классическими» клинико-морфологическими характеристиками (в первую очередь со стадией опухолевого процесса), так как именно они определяют прогностические свойства опухоли.

14 February 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
GRG.A. Raskin
G.A. Raskin
MMM.S. Mukhina
M.S. Mukhina
AKA.S. Kaurtseva
A.S. Kaurtseva
YAYu.YU. Andreeva
Yu.YU. Andreeva
LZL.E. Zavalishina
L.E. Zavalishina
ROR.V. Orlova
R.V. Orlova
Microsatellite instability, which is caused by a deficiency in the DNA unpaired nucleotide repair system, is an important pathogenetic event for some tumors. In addition, the detection of this molecular feature becomes an independent prognostic factor in the course of the disease and a predictor for the appointment of therapy with immune checkpoint inhibitors. Immunohistochemistry is a reliable and available method for detecting a deficiency in the DNA mismatch repair system, and it has recommended as a screening for hereditary syndromes associated with microsatellite instability. This article discusses the advantages and disadvantages of this research method from the point of view of the practitioner.